A large observational study found a higher rate of regurgitation or pulmonary aspiration among patients taking GLP-1 drugs before anesthetic care, but absolute event numbers were small and the study does not prove the medications caused the events.
In a UK study of >47,000 patients, 1.41% of GLP-1 users experienced regurgitation or aspiration during anesthetic care versus 0.12% of non-users.
The study reported an approximately 11-fold relative increase in the combined outcome for GLP-1 users, driven mainly by regurgitation events.
# What the study measured A study published in Anaesthesia followed more than 47,000 patients receiving anesthetic care across multiple UK centers. Researchers compared outcomes between 1,348 patients taking GLP-1 medications (such as semaglutide or tirzepatide) and 45,691 patients not taking these drugs. The combined outcome was regurgitation or pulmonary aspiration occurring during anesthetic care.
# The headline result and what it means Nineteen of the GLP-1 users experienced regurgitation or aspiration events, an event rate of 1.41%. Among non-users the combined event rate was 0.12%. The researchers reported an about 11-fold higher rate for the combined outcome in GLP-1 users.
# Why GLP-1 drugs might affect anesthesia risk GLP-1 medications slow stomach emptying as part of their effects on appetite and blood glucose. Standard preoperative fasting aims to reduce stomach contents before anesthesia because anesthesia suppresses airway-protective reflexes. If digestion is delayed, some patients may still have residual stomach contents despite following typical fasting guidance, which could increase the chance of regurgitation and, in some cases, aspiration into the lungs.
# Limits of the study and remaining uncertainty
# What current guidance says for U.S. patients U.S. professional guidance (American Society of Anesthesiologists) does not instruct all patients to stop GLP-1 medications before elective procedures. Instead, clinicians should assess each patient's individual risk. Extra precautions may be considered for patients who have recently started or increased dose, have gastrointestinal symptoms such as nausea or bloating, take higher doses linked to more GI side effects, or have other conditions that slow gastric emptying.
Suggested precautions for higher-risk patients described by clinicians include a 24-hour liquid-only diet before anesthesia, adjusting the anesthesia approach, or using bedside stomach ultrasound to check gastric contents.
# Practical next steps for patients scheduled for surgery Do not stop GLP-1 medications on your own. Tell your surgical and anesthesia teams exactly which medications you take, the dose, and when you started or changed the dose. Report any current GI symptoms. Your clinicians can then tailor fasting instructions or consider additional measures to reduce regurgitation and aspiration risk during anesthetic care.
# Bottom line The UK study found a higher rate of regurgitation or aspiration during anesthesia among GLP-1 users, but absolute event counts were small and causation was not established. The immediate action for patients is clear: communicate medication use and symptoms to your surgical team so they can individualize preoperative planning and anesthesia management.
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
Millions of Americans are losing significant weight on GLP-1 medications like Ozempic and Wegovy, but for a growing number of patients, that weight loss is coming with a side effect they never anticipated: a face that suddenly looks years older. Dr. Pamela Brownlee, a double board-certified plastic surgeon in Frisco, s
Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials a
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related
Semaglutide has become famous for what it does to the waistline. But researchers are increasingly interested in what GLP-1 drugs might be doing elsewhere in the body. Now a large new study suggests semaglutide may be associated with lower rates of several neurological and psychiatric problems—and researchers found evid
This World News Day, Rappler celebrates what makes news worth reading, remembering, and supporting — and opens the Rappler+ community to more people with a special annual rate of P2,800 from September 23 to 28
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.